Serum and tissue biomarkers associated with CRESS and STAR response to B ‐cell targeted therapy in TRACTISS trial of Sjogren's syndrome

ConclusionsRituximab modulates both peripheral and SG inflammation, preventing the deterioration of exocrine function linked with functional and metabolic restoration of the glandular epithelium. Response assessed by newly developed cCRESS and STAR criteria was associated with differential modulation of peripheral and SG biomarkers, emerging as novel tools for patient stratification.

Source: Arthritis and Rheumatology - December 11, 2023 Category: Rheumatology Authors: E Pontarini, E Sciacca, F Chowdhury, S Grigoriadou, F Rivellese, WJ Murray ‐Brown, D Lucchesi, L Fossati‐Jimack, A Nerviani, E Jaworska, GM Ghirardi, C Giacomassi, P Emery, WF Ng, N Sutcliffe, CC Everett, C Fernandez, AR Tappuni, R S Tags: Full Length Source Type: research